U.S. flag An official website of the United States government
  1. Home
  2. Advisory Committees
  3. Advisory Committee Calendar
  4. May 18, 2023: Tobacco Products Scientific Advisory Committee Meeting - 05/18/2023
  1. Advisory Committee Calendar

Advisory Committee Meeting

Event Title
May 18, 2023: Tobacco Products Scientific Advisory Committee Meeting
May 18, 2023


Date:
May 18, 2023
Time:
9:00 AM - 2:00 PM ET
Location:
Event Location
White Oak Campus: The Great Room
Conference Center

10903 New Hampshire Ave
Building 31, Room 1503
Silver Spring, MD 20993
United States



What is an advisory committee?

Advisory committees provide independent expert advice to the FDA on broad scientific topics or on certain products to help the agency make sound decisions based on the available science. Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so. Please see, "Advisory Committees Give FDA Critical Advice and the Public a Voice," for more information.


Agenda

On May 18, 2023, the Center for Tobacco Products (CTP) Tobacco Products Scientific Advisory Committee (TPSAC) will meet in open session to discuss and provide an opportunity for recommendations on the proposed Requirements for Tobacco Product Manufacturing Practice rule (proposed 21 CFR part 1120).  The meeting will be open to the public.  


Meeting Materials

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s website after the meeting.

Materials for this meeting will be available at the Tobacco Products Scientific Advisory Committee meetings main page.


Public Participation Information

Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.

  • FDA has established a docket for public comment (Docket No. FDA-2013-N-0227). Either electronic or written comments on this public advisory committee meeting must be submitted by May 11, 2023, for consideration by the committee.
  • On May 18, 2023, oral presentations from the public will be scheduled between approximately 9:30 a.m. and 10:30 a.m. 

Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, along with their names, email addresses, and direct contact phone numbers of proposed participants, on or before 12 p.m. Eastern Time on May 3, 2023.  Time allotted for each presentation may be limited.  If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.  The contact person will notify interested persons regarding their request to speak by 6 p.m. May 4, 2023. 

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

There will be no food or beverage available for purchase on the FDA campus. Please plan accordingly.  We apologize for this inconvenience.

For those unable to attend in person, the meeting will also be available via webcast.


Contact Information

  • CAPT Serina Hunter-Thomas, 240-402-5771, e-mail: [email protected] 
  • FDA Advisory Committee Information Line: 1-800-741-8138 (301-443-0572 in the Washington, DC area) Please call the Information Line for up-to-date information on this meeting.

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the meetings main page or call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. 

If you require special accommodations due to a disability, please contact Serina Hunter-Thomas at least 7 days in advance of the meeting.

Information regarding ground transportation, airport information, lodging, driving directions, visitor parking, and security can be accessed at the public meetings at White Oak main page.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Official FR Notice


A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s website or call the committee’s Designated Federal Officer (see Contact Information) to learn about possible modifications before coming to the meeting.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact the committee’s Designated Federal Officer (see Contact Information) at least 7 days in advance of the meeting.

Answers to commonly asked questions including information regarding special accommodations due to a disability may be accessed at: Common Questions and Answers about FDA Advisory Committee Meetings.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at Public Conduct During FDA Advisory Committee Meetings for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).

Back to Top